Validation of a prognostic 53-immune-gene panel in stage II/III melanoma.

Margaret Borgardus,Robyn Gartrell,Douglas Kanter Marks,Camden L Esancy,Sarabjot Pabla,Marc S. Ernstoff,John M. Kirkwood,Rui R. Chang,Bret Taback,Sandra J. Lee,John J. Krolewski,Carl Morrison,Yvonne M. Saenger

Validation of a prognostic 53-immune-gene panel in stage II/III melanoma.

2018

Margaret Borgardus
Robyn Gartrell
Douglas Kanter Marks
Camden L Esancy
Sarabjot Pabla
Marc S. Ernstoff
John M. Kirkwood
Rui R. Chang
Bret Taback
Sandra J. Lee
John J. Krolewski
Carl Morrison
Yvonne M. Saenger

9576Background: Patients with resected stage II/III melanoma are at high risk of systemic metastasis and prognostic indices to stratify these patients for adjuvant immunotherapy. We previously defi...

Keywords:

Melanoma
Immune system
Pathology
Cancer research
Gene
Medicine
Immunotherapy
Adjuvant
stage ii
Oncology
Internal medicine
systemic metastasis
immune gene

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations